Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

CD79B and MYD88 mutations in diffuse large B-cell lymphoma.

Kim Y, Ju H, Kim DH, Yoo HY, Kim SJ, Kim WS, Ko YH.

Hum Pathol. 2014 Mar;45(3):556-64. doi: 10.1016/j.humpath.2013.10.023. Epub 2013 Oct 31.

PMID:
24444466
2.

Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.

Taniguchi K, Takata K, Chuang SS, Miyata-Takata T, Sato Y, Satou A, Hashimoto Y, Tamura M, Nagakita K, Ohnishi N, Noujima-Harada M, Tabata T, Kikuti YY, Maeda Y, Nakamura N, Tanimoto M, Yoshino T.

Am J Surg Pathol. 2016 Mar;40(3):324-34. doi: 10.1097/PAS.0000000000000592.

PMID:
26752547
3.

Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.

Yamada S, Ishida Y, Matsuno A, Yamazaki K.

Leuk Lymphoma. 2015 Jul;56(7):2141-5. doi: 10.3109/10428194.2014.979413. Epub 2015 Jan 14.

PMID:
25347427
4.

MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.

Takeuchi T, Yamaguchi M, Kobayashi K, Miyazaki K, Tawara I, Imai H, Ono R, Nosaka T, Tanaka K, Katayama N.

Cancer. 2017 Apr 1;123(7):1166-1173. doi: 10.1002/cncr.30404. Epub 2016 Dec 4.

PMID:
27915469
5.

Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.

Cao XX, Li J, Cai H, Zhang W, Duan MH, Zhou DB.

Ann Hematol. 2017 Nov;96(11):1867-1871. doi: 10.1007/s00277-017-3094-7. Epub 2017 Aug 12.

PMID:
28803429
6.

MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.

Choi JW, Kim Y, Lee JH, Kim YS.

Hum Pathol. 2013 Jul;44(7):1375-81. doi: 10.1016/j.humpath.2012.10.026. Epub 2013 Feb 4.

PMID:
23380077
7.

Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.

Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, Tanaka K, Fukushima S, Takami H, Arita H, Kubo A, Shuto T, Ohno M, Miyakita Y, Kocialkowski S, Sasayama T, Hashimoto N, Maehara T, Shibui S, Ushijima T, Kawahara N, Narita Y, Ichimura K.

Neuropathol Appl Neurobiol. 2016 Apr;42(3):279-90. doi: 10.1111/nan.12259. Epub 2015 Jul 20.

PMID:
26111727
8.

Oncogenically active MYD88 mutations in human lymphoma.

Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM.

Nature. 2011 Feb 3;470(7332):115-9. doi: 10.1038/nature09671. Epub 2010 Dec 22.

9.

Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly.

Gebauer N, Gebauer J, Hardel TT, Bernard V, Biersack H, Lehnert H, Rades D, Feller AC, Thorns C.

Leuk Lymphoma. 2015 Apr;56(4):1100-6. doi: 10.3109/10428194.2014.944522. Epub 2014 Aug 21.

PMID:
25030036
10.

High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.

Pham-Ledard A, Beylot-Barry M, Barbe C, Leduc M, Petrella T, Vergier B, Martinez F, Cappellen D, Merlio JP, Grange F.

JAMA Dermatol. 2014 Nov;150(11):1173-9. doi: 10.1001/jamadermatol.2014.821.

PMID:
25055137
11.

Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.

Bohers E, Mareschal S, Bouzelfen A, Marchand V, Ruminy P, Maingonnat C, Ménard AL, Etancelin P, Bertrand P, Dubois S, Alcantara M, Bastard C, Tilly H, Jardin F.

Genes Chromosomes Cancer. 2014 Feb;53(2):144-53. doi: 10.1002/gcc.22126. Epub 2013 Nov 5.

PMID:
24327543
12.

Synergistic cooperation and crosstalk between MYD88L265P and mutations that dysregulate CD79B and surface IgM.

Wang JQ, Jeelall YS, Humburg P, Batchelor EL, Kaya SM, Yoo HM, Goodnow CC, Horikawa K.

J Exp Med. 2017 Sep 4;214(9):2759-2776. doi: 10.1084/jem.20161454. Epub 2017 Jul 12.

PMID:
28701369
13.

Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocation.

Santos Gda C, Saieg MA, Ko HM, Geddie WR, Boerner SL, Craddock KJ, Crump M, Bailey D.

Cancer Cytopathol. 2015 Jul;123(7):413-20. doi: 10.1002/cncy.21535. Epub 2015 Mar 23.

14.

B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.

Knittel G, Liedgens P, Korovkina D, Seeger JM, Al-Baldawi Y, Al-Maarri M, Fritz C, Vlantis K, Bezhanova S, Scheel AH, Wolz OO, Reimann M, Möller P, López C, Schlesner M, Lohneis P, Weber AN, Trümper L; German International Cancer Genome Consortium Molecular Mechanisms in Malignant Lymphoma by Sequencing Project Consortium, Staudt LM, Ortmann M, Pasparakis M, Siebert R, Schmitt CA, Klatt AR, Wunderlich FT, Schäfer SC, Persigehl T, Montesinos-Rongen M, Odenthal M, Büttner R, Frenzel LP, Kashkar H, Reinhardt HC.

Blood. 2016 Jun 2;127(22):2732-41. doi: 10.1182/blood-2015-11-684183. Epub 2016 Apr 5.

15.

Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.

Zheng M, Perry AM, Bierman P, Loberiza F Jr, Nasr MR, Szwajcer D, Del Bigio MR, Smith LM, Zhang W, Greiner TC.

Neuropathology. 2017 Aug 30. doi: 10.1111/neup.12405. [Epub ahead of print]

PMID:
28856744
16.

High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.

Kraan W, van Keimpema M, Horlings HM, Schilder-Tol EJ, Oud ME, Noorduyn LA, Kluin PM, Kersten MJ, Spaargaren M, Pals ST.

Leukemia. 2014 Mar;28(3):719-20. doi: 10.1038/leu.2013.348. Epub 2013 Nov 20. No abstract available.

PMID:
24253023
17.

High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.

Oishi N, Kondo T, Nakazawa T, Mochizuki K, Tanioka F, Oyama T, Yamamoto T, Iizuka J, Tanabe K, Shibata N, Kirito K, Katoh R.

Pathol Int. 2015 Oct;65(10):528-35. doi: 10.1111/pin.12336. Epub 2015 Aug 4.

PMID:
26388135
18.

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM.

Nature. 2010 Jan 7;463(7277):88-92. doi: 10.1038/nature08638.

19.

Development of high-resolution melting analysis for the detection of the MYD88 L265P mutation.

Wang CZ, Lin J, Qian J, Shao R, Xue D, Qian W, Xiao GF, Deng ZQ, Yang J, Li Y, Chen XX.

Clin Biochem. 2013 Mar;46(4-5):385-7. doi: 10.1016/j.clinbiochem.2012.11.007. Epub 2012 Nov 21.

PMID:
23178471
20.

Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.

Kersten MJ, Kraan W, Doorduijn J, Bromberg J, Lam K, Kluin PM, van der Holt BJ, Spaargaren M, Pals ST.

Blood Cancer J. 2014 Dec 12;4:e266. doi: 10.1038/bcj.2014.87. No abstract available.

Supplemental Content

Support Center